Clinsys Enters EDC Niche

Monday, December 8, 2008

One company’s bad luck became another’s good fortune with Clinsys Clinical Research’s recent acquisition of a new electronic data capture (EDC) platform, TrialStat ClinicalAnalytics (TrialStat CA).

[Read More]

CROs Add New People, Positions

Thursday, December 4, 2008

Although many companies are reducing headcount at an alarming rate, at least a few contract research organizations (CROs) continue to hire new people and create new positions. This week’s personnel news from around the clinical trial industry:

[Read More]

WuXi Cuts U.S. Manufacturing Business

Wednesday, December 3, 2008

Chinese contract research organization (CRO) WuXi PharmaTech is discontinuing its U.S. biologics manufacturing operations as of December 31. As a result, the company will cut about 100 manufacturing and supporting positions at its Philadelphia facility.

[Read More]

Clinilabs Names Greenberg Director of Expanded Unit

Wednesday, November 26, 2008

New York, NY-based contract research organization (CRO) Clinilabs appointed Howard Greenberg, M.D., senior medical director of the company’s newly expanded clinical pharmacology unit. Greenberg has served as the principal investigator or co-investigator for more than 100 clinical trials and co-authored more than 30 peer-reviewed research publications. Most recently, he was group medical director at Bristol-Meyers Squibb.

[Read More]

SFDA, Big Pharma Share Concerns at Shanghai Conference

Monday, November 24, 2008

In his regulatory keynote address at the China Trials 2008 conference in Shanghai, Dr. Yi Feng, director, Office of Review Management, Center for Drug Evaluation (CDE), State Food and Drug Administration (CFDA) gave a broad overview of the evolution of global clinical trials in China and pinpointed future trends and goals in the country.

[Read More]

Rural Population Key to China’s Clinical Research Market

Friday, November 21, 2008

In his presentation at China Trials 2008 in Shanghai, “Conducting Global Post-Marketing Surveillance Studies in China—Opportunity and Practical Issues,” Mark Engel, president and chairman of Excel PharmaStudies, a large China-based contract research organization, identified two megatrends that will drive post-marketing surveillance studies to China: the rapid aging of its population and its increasingly insured rural population.

[Read More]